Last week, Ascendis Pharma A/S (NASDAQ:ASND) released topline data on Monday from a trial that included 84 children with achondroplasia, a genetic disorder that causes dwarfism and disproportionate short stature.
Goldman Sachs hosted an investor meeting with BioMarin Pharmaceutical Inc's (NASDAQ:BMRN) Alexander Hardy (President and CEO) and Brian Mueller (EVP, CFO).
They reiterated financial guidance after reviewing their assumptions around Voxzogo competition post-Ascendis Pharma's better-than-expected Phase 3 achondroplasia data.
Also Read: Rare Disease-Focused BioMarin Narrows Sales Focus, Cuts Cost For Hemophilia A Gene Therapy; Lifts Annual Guidance.
The analyst notes that management believes a U.S./EU launch by Ascendis Pharma could violate its C-type natriuretic